The mean of analysts' price targets for Oculis Holding AG (OCS) points to a 199.8% upside in the sto

Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused o

ZUG, Switzerland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting

JP Morgan analyst Tessa Romero maintains Oculis Holding (NASDAQ:OCS) with a Overweight and lowers

The average of price targets set by Wall Street analysts indicates a potential upside of 187.8% in O

Transaction will enhance Oculis’ strategic flexibility and ownership of Privosegtor while driving lo

ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (

Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.20) per share which beat the analyst co

Oculis Holding AG (OCS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus

ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Ocu

HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and main

The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privose

The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privose

ZUG, Switzerland, Aug. 03, 2026 (GLOBE NEWSWIRE) -- The FDA Division of Neurology provided positive

British outsourcer Mitie ‌has agreed to be acquired by rival OCS Group ​International for a ​total v

U.S. stock futures lower, Nasdaq 100 down 2%. Intuitive Surgical shares dip 11.3% after Q2 earnings

ZUG, Switzerland, July 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting

ZUG, Switzerland, July 2, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Compan

NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

NEW YORK, June 18, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

LOS ANGELES, June 17, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights li

NEW YORK, June 16, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

LOS ANGELES, June 11, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litiga

NEW YORK, June 11, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Ocu

PREDICT-1 is the first genotype-based registrational trial in dry eye disease (DED), with the potent

JP Morgan analyst Tessa Romero maintains Oculis Holding (NASDAQ:OCS) with a Overweight and lowers

Baird analyst Colleen Kusy maintains Oculis Holding (NASDAQ:OCS) with a Outperform and lowers the

Stifel analyst Annabel Samimy maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the pri

Oculis (OCS) stock plummets 37% after its Phase 3 DIAMOND trials for diabetic macular edema fail to

Guggenheim analyst Yatin Suneja maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the p

Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price tar

Needham analyst Serge Belanger maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowers the pr

HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and lowe

Taylor Morrison Home soared 23.28% to $72.12 in pre-market trading after Berkshire Hathaway announce

The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52

Guggenheim analyst Yatin Suneja initiates coverage on Oculis Holding (NASDAQ:OCS) with a Buy rati

JP Morgan analyst Tessa Romero maintains Oculis Holding (NASDAQ:OCS) with a Overweight and raises

Needham analyst Serge Belanger maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the pr

HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and rais

Oculis Holding (NASDAQ:OCS) reported quarterly losses of $(0.63) per share which missed the analyst

HC Wainwright & Co. analyst Yi Chen reiterates Oculis Holding (NASDAQ:OCS) with a Buy and mai

Last patient visits for both OCS-01 Phase 3 DIAMOND trials (total 800+ patients) are complete, with

PRIME designation follows recent Breakthrough Therapy designation from the U.S. FDA, underscoring th

Stifel analyst Annabel Samimy maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the pri

HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and rais